2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 335

Renal Transplant Complications in Patients with and Without Gout

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 236

Repeat Muscle Pressures Measured in Fibromyalgia Patients and Compared with Pain Scores

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 592

Replacement of Radiographic Sacroilitis by MRI Structural Lesions: What Is the Impact on Classification of Axial Spondyloarthritis in the ASAS Classification Cohort?

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 578

Restricted Work Participation Relates to High Disease Activity in Spondyloarthritis Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 611

Retina of Ankylosing Spondylitis Patients Shows Early Signs of Atherosclerotic Disease in Comparison with Healthy Controls

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 383

Retroperitoneal Fibrosis- a Single Center Experience

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 699

Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 582

Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 260

Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 550

Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 342

Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 734

Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 202

Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 351

Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnameses: Results of a Prospective Study in Ho Chi Minh City

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 732

Risk of Heart Valve Disease in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].